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Topic: This study evaluated the cardiovascular/cerebrovascular safety proﬁle of ranibizumab 0.5 mg versus
sham  verteporﬁn in patients with neovascular age-related macular degeneration (nAMD). In addition, com-
parisons of ranibizumab 0.3 mg with sham and ranibizumab 0.5 mg to 0.3 mg were performed.
Clinical Relevance: Intravitreal antievascular endothelial growth factor (VEGF) agents carry potential
increased systemic risks, including cardiovascular or cerebrovascular events. Pooled safety analyses allow better
interpretation of safety outcomes seen in individual clinical trials, especially for less common events. To our
knowledge, this is the largest patient-level pooled analysis of patients with nAMD treated with ranibizumab.
Methods: Patient-level pooled analysis of data from 7 Genentech- and Novartis-sponsored phase II, III, and IV
studies in nAMD that were completed by December 31, 2013. Pairwise comparisons (primary comparison: ranibizumab
0.5 mg [globally approved dose for nAMD] vs. sham or verteporﬁn) were performed using Cox proportional hazard
regression (hazard ratios [HRs], 95% conﬁdence intervals [CIs]) and rates per 100 patient-years. StandardizedMedical
Dictionary forRegulatoryActivitiesqueries (SMQs)andextendedsearcheswereused to identify relevantsafetyendpoints,
includingarterial thromboembolicevents (ATEs),myocardial infarction (MI), strokeor transient ischemicattack (TIA), stroke
(excluding TIA), vascular deaths, andmajor vascular events as deﬁned by the Antiplatelet Trialists’ Collaboration (APTC).
Results: The HRs (95% CIs) for the primary comparison of ranibizumab 0.5 mg (n¼480) versus sham or
verteporﬁn (n¼462) were 1.16 (0.72e1.88) for ATE, 1.33 (0.59e2.97) for MI, 1.43 (0.54e3.77) for stroke excluding
TIA, 1.25 (0.61e2.55) for stroke or TIA, 0.57 (0.18e1.78) for vascular death, and 1.12 (0.64e1.98) for APTC events.
Hazard ratio 95% CIs included 1, indicating no signiﬁcant treatment differences, for all endpoints for comparison
of ranibizumab 0.5 mg versus sham or verteporﬁn.
Conclusions: The rates of cardiovascular and cerebrovascular events were low in these patients with nAMD
and not clinically meaningfully different for patients treated with ranibizumab 0.5 mg versus sham or verteporﬁn,
which supports the favorable beneﬁterisk proﬁle of ranibizumab in the patient population with nAMD. Pooling
these studies allows an analysis with higher power and precision compared with individual study
analyses. Ophthalmology Retina 2018;2:1087-1096 ª 2018 by the American Academy of Ophthalmology. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).See Editorial on page 1085.Supplemental material available at www.ophthalmologyretina.org.Intravitreal antievascular endothelial growth factor
(VEGF) agents have demonstrated safety and efﬁcacy in
large, controlled clinical trials in a number of retinal
diseases, including neovascular age-related macular
degeneration (nAMD), macular edema secondary to
retinal vein occlusions, choroidal neovascularization
secondary to pathological myopia, and diabetic eye
disease, including diabetic macular edema, proliferative
diabetic retinopathy, and diabetic retinopathy, in patients
with diabetic macular edema. The safety and efﬁcacy of
the anti-VEGF biological agent that has been studied 2018 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.the most extensively, ranibizumab (Lucentis, Genentech,
Inc, South San Francisco, CA; Novartis Pharma,
Basel, Switzerland), have been evaluated in multiple
large, randomized, controlled clinical trials across
retinal vascular diseases involving VEGF, including
nAMD.1-4 Ranibizumab is an afﬁnity-matured mono-
clonal antibody fragment designed for intraocular use
speciﬁcally without an Fc domain, leading to a shorter
systemic half-life.5
In studies of the anti-VEGF agent bevacizumab, a full-
length antibody with an active Fc domain, an increased risk1087https://doi.org/10.1016/j.oret.2018.04.018
ISSN 2468-6530/18
Ophthalmology Retina Volume 2, Number 11, November 2018of cardiovascular and cerebrovascular events was observed
when it was administered systemically via intravenous in-
fusions to oncology patients in much greater doses than for
ophthalmic use (>5 mg/kg of body weight biweekly).6
Intravitreal injections of ranibizumab and other anti-VEGF
agents for ophthalmologic indications deliver much lower
doses (0.3 mg to 0.5 mg for ranibizumab, 1.25 mg for bev-
acizumab,7,8 and 2.0 mg for aﬂibercept,9 not more frequently
than monthly), which egress into the systemic circulation and
may still have a potential for systemic safety risks.
Available data regarding a potential association between
age-related macular degeneration (AMD) and cardiovascu-
lar and cerebrovascular disease are mixed.10,11 In a diverse
population of men and women aged 45 to 84 years, there
were no signiﬁcant differences in the rates of incident
cardiovascular disease between patients with AMD and
those without, although there was a higher incidence of
events in patients with advanced AMD compared with those
without AMD.10 Several studies have identiﬁed an increased
risk of stroke in patients with nAMD.12-15
Pooled safety analyses can provide more precise and ac-
curate estimates of safety outcomes, particularly for less
common adverse events (AEs), and can potentially identify
features that are not apparent in individual studies. In this
pooled analysis, the combination of patient-level safety data
across multiple (US and global), randomized, controlled
studies increases the potential to detect treatment differences
for less common AEs. This pooled analysis of patient-level
data also incorporates more information (e.g., patient-level
baseline risk factors and timing of each individual event
with respect to drug exposure) compared with most traditional
meta-analyses based on published study-level data. The
objective of this analysis is for Novartis and Genentech to
provide the retinal community the cumulative global experi-
ence in evaluating the safety of ranibizumab by pooling results
across company-sponsored clinical trials in nAMD.
Methods
A formal statistical analysis plan was prespeciﬁed before the start
of this project, deﬁning study inclusion criteria, deﬁnition of end-
points, classiﬁcation of potential risk factors, and analysis methods.
Study Selection
Phase II, III, and IV randomized, double-masked studies in patients
with nAMD sponsored by Genentech, Inc, or Novartis Pharma,
which were designed and conducted to meet regulatory standards
set by the health authorities in the relevant countries, were
considered for this analysis. For inclusion in this pooled analysis,
each study was required to have at least 2 of the following 3
treatment arms: ranibizumab 0.5 mg with or without adjunctive
verteporﬁn, ranibizumab 0.3 mg with or without adjunctive ver-
teporﬁn, or a sham or verteporﬁn arm, with a completion/cutoff
date before December 31, 2013. Seven trials met these criteria:
Anti-VEGF Antibody for the Treatment of Predominantly Classic
Choroidal Neovascularization in Age-Related Macular Degenera-
tion (ANCHOR),1,2 Minimally Classic/Occult Trial of the Anti-
VEGF Antibody Ranibizumab in the Treatment of Neovascular
AMD (MARINA),4 Phase IIIb, multicenter, randomized, double-
masked, sham injectionecontrolled study of the efﬁcacy and
safety of ranibizumab in subjects with subfoveal CNV with or1088without classic CNV secondary to AMD (PIER),16,17 Safety
Assessment of Intravitreous Lucentis for AMD (SAILOR),18
Efﬁcacy and safety of verteporﬁn photodynamic therapy in
combination with ranibizumab or alone versus ranibizumab
monotherapy in patients with symptomatic macular polypoidal
choroidal vasculopathy (EVEREST),19 Safety and efﬁcacy of
ranibizumab in Japanese patients with subfoveal choroidal
neovascularization secondary to age-related macular degeneration
(EXTEND I),20 and Efﬁcacy and Safety of Ranibizumab in
Patients With Subfoveal Choroidal Neovascularization (CNV)
Secondary to Age-related Macular Degeneration (EXCITE).21
Study of Ranibizumab Administered Monthly or on an As-
needed Basis in Patients With Subfoveal Neovascular Age-
related Macular Degeneration (HARBOR), a more recent study
comparing ranibizumab 0.5 mg with 2.0 mg, did not meet study
selection criteria because it did not include a ranibizumab
0.3-mg, sham, or verteporﬁn control arm.3,22 All 7 studies were
conducted in compliance with the tenets of the Declaration of
Helsinki. The independent ethics committee or institutional review
boards approved the studies, and all patients provided written
informed consent before enrollment, which extended to the use of
individual patient data for further analyses.
Endpoint Selection
Patient-level data available from the pooled safety database included
AEs, timing of AEs, demographic data, key potential baseline risk
factors obtained from patient medical history, baseline concomitant
medications, and dosing information/drug exposure. The selected
safety endpoints have been described previously.23 This article’s
focus is on cardiovascular and cerebrovascular (arteriovascular)
endpoints, which are recognized potential AEs of agents that
target the VEGF pathway.6 The analysis used Standardized
Medical Dictionary for Regulatory Activities Queries (SMQs)
whenever possible (Medical Dictionary for Regulatory Activities
Version 16.1; Table S1, available at www.ophthalmologyretina.org).
If speciﬁc SMQs were not available, the analysis used prospectively
developed composite safety endpoints (based on a combination of
SMQs or inclusion of a collection of preferred terms). The 6 key
arteriovascular endpoints were arterial thromboembolic events
(ATEs), myocardial infarction (MI), stroke or transient ischemic
attack (TIA), stroke (excluding TIA), vascular death, and
Antiplatelet Trialists’ Collaboration (APTC) events. This analysis
also evaluated other systemic events.
Pairwise Comparisons of Interventions
Patients were categorized into 3 groups based on their initial
treatment: (1) ranibizumab 0.5 mg with or without verteporﬁn, (2)
ranibizumab 0.3 mg, and (3) sham with or without verteporﬁn,
abbreviated as (1) ranibizumab 0.5 mg, (2) ranibizumab 0.3 mg,
and (3) sham in this article, respectively. The primary comparison
is ranibizumab 0.5 mg versus sham because this is the approved
dose for treatment of nAMD globally.24,25 Additional comparisons
include ranibizumab 0.3 mg versus sham and ranibizumab 0.5 mg
versus ranibizumab 0.3 mg. To be included in a particular pairwise
comparison, the individual study must have compared both treat-
ment groups. This analysis combined studies with monthly dosing
with those allowing pro re nata (PRN) or quarterly dosing.
Statistical Analysis
Only the ﬁrst event was included in the analysis for patients with
multiple events reported for the same endpoint; thus, for a given
endpoint, each patient is only counted once. For composite end-
points such as APTC, for which a patient may have multiple events
(e.g., stroke and MI), only time to the ﬁrst event is included in the
Figure 1. Pairwise comparisons of cardiovascular and cerebrovascular events in ranibizumab 0.5 mg, ranibizumab 0.3 mg, and sham.a Horizontal bars are
95% conﬁdence intervals (CIs) of the hazard ratio (HR), reported as Trt 2 vs Trt 1. aCox regression, stratiﬁed by study. bInteraction test for homogeneity
from global Cox regression model adjusting for baseline risk factors. Numbers in the table are rates per 100 patient-years (Rate) and the number of subjects
with the event (n)/number of subjects (N)/number of patient-years (PY). APTC ¼ Antiplatelet Trialists’ Collaboration; ATE ¼ arterial thromboembolic
events; TIA ¼ transient ischemic attack; Trt ¼ treatment.
Zarbin et al  Pooled Safety Analysis of Ranibizumab in nAMDanalysis. Because of differing lengths of patient follow-up in the
various studies, this analysis reports event rates for comparative
purposes as rates per 100 patient-years of exposure. In addition, the
percentage of patients is provided. This analysis censored sham
patients who crossed over to ranibizumab therapy following the
controlled portion of the studies at the time of their ﬁrst ranibi-
zumab exposure, and used the timing of each safety event relative
to baseline for each patient, allowing the pooling of studies of
differing durations. There were no adjustments for multiplicity.
Two modeling approaches used were: (1) separate proportional
hazard Cox regression models (stratiﬁed by study), ﬁt for each pair-
wise comparison and each endpoint unadjusted for baseline risk
factors; and (2) global Cox regression models (stratiﬁed by study),
which incorporated all pairwise comparisons adjusting for baseline
risk factors (Table S2, available at www.ophthalmologyretina.org).
For all models, separate and global, to assess homogeneity across
studies, the study by treatment interaction term was included. Cox
proportional hazard regression models allow for combining studies
of different durations and incorporate the timing of each endpoint
for each patient. Forest plots show study level and pooled estimates
of relevant hazard ratios (HRs), 95% conﬁdence intervals (CIs), and
interaction test results. KaplaneMeier plots show the cumulative
events over time, by treatment for select endpoints.Results
Study and Baseline Characteristics
The pooled dataset included 4080 total patients, whereas for the
pairwise comparison of ranibizumab 0.5 mg versus sham, there were
480 and 462 patients, respectively (ANCHOR, MARINA, PIER,EVEREST). For the comparison of ranibizumab 0.3 mg versus
sham, there were 434 and 441 patients, respectively (ANCHOR,
MARINA, PIER). For ranibizumab 0.5 mg versus 0.3 mg, there
were 1814 and 1764 patients, respectively (MARINA, ANCHOR,
PIER, SAILOR, EXTEND I, EXCITE). There were differing study
designs, patient demographics, geographic regions, inclusion and
exclusion criteria, treatment durations, ranibizumab dosing regi-
mens, and PRN re-treatment criteria across the included studies.
Overall, 426, 179, and 1249 patients were treated monthly, quar-
terly, and PRN in the ranibizumab 0.5 mg group; 416, 179, and 1169
patients were treated monthly, quarterly, and PRN in the ranibizu-
mab 0.3 mg group; and 379, 62, and 21 patients were treated
monthly, quarterly, and PRN in the sham group, respectively.
Cardiovascular and cerebrovascular inclusion and exclusion
criteria varied among studies. ANCHOR, MARINA, and PIER (in
total, 1315 [32%] of 4080 patients in the pooled data set and 94%
for the primary comparison sham vs. 0.5 mg) had no speciﬁc
cardiovascular or cerebrovascular exclusion criteria. EVEREST,
EXTEND I, and EXCITE excluded patients with a prior
cardiovascular accident (CVA). SAILOR excluded patients if
cardiovascular disease was uncontrolled.18 There was no evidence
for inhomogeneity of the studies as based on study by treatment
interactions (Fig 1). Generally, treatment groups were well
balanced for each of the potential risk factors (Table S2,
available at www.ophthalmologyretina.org).
Cardiovascular and Cerebrovascular Events
Rates of overall ATEs, MI, stroke (excluding TIA), stroke or TIA,
vascular death, and APTC events were similar for both the1089
Figure 2. Pairwise comparisons by study of key cardiovascular and cerebrovascular endpoints.a Arterial thromboembolic events (A), myocardial infarction (MI)
(B), stroke (excluding TIA) (C), stroke or TIA (D), vascular death (E), andAPTC (F) by study and overall. Horizontal bars are 95% conﬁdence intervals (CIs) of
the hazard ratio (HR), reported as Trt 2 vs Trt 1. aCox regression, stratiﬁed by study. Numbers in the table are rates per 100 patient-years (Rate) and the number of
subjects with the event (n)/number of subjects (N)/number of patient-years (PY). ANCHOR¼Anti-VEGFAntibody for the Treatment of Predominantly Classic
Choroidal Neovascularization in Age-Related Macular Degeneration; APTC ¼ Antiplatelet Trialists’ Collaboration; C1 ¼ cohort 1; EVEREST ¼ Efﬁcacy and
safety of verteporﬁn photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular
polypoidal choroidal vasculopathy; EXCITE¼ Efﬁcacy and safety of ranibizumab in patients with Subfoveal Choroidal Neovascularization (CNV) secondary to
age-relatedmacular degeneration;EXTEND¼Safety and efﬁcacyof ranibizumab in Japanesepatientswith subfoveal choroidal neovascularization secondary to age-
related macular degeneration; MARINA¼Minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular AMD; PIER¼
Phase IIIb,multicenter, randomized, double-masked, shaminjectionecontrolled studyof the efﬁcacy and safety of ranibizumab in subjectswith subfovealCNVwith
or without classic CNV secondary to AMD; SAILOR¼ Safety assessment of intravitreous lucentis for AMD; TIA¼ transient ischemic attack; Trt¼ treatment.
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Table 3. Incidence of Systemic Events
Event Study
Comparison Treatment 1
vs. Treatment 2
Treatment
1 n/N (%)
Treatment
2 n/N (%)
Treatment 1 Rate
per 100 Patient-Years
Treatment 2 Rate
per 100 Patient-Years
ATEs MARINA4 Sham vs. ranibizumab 0.3 mg 13/236 (5.5) 17/238 (7.1) 3.14 (13/236/415) 3.85 (17/238/442)
Sham vs. ranibizumab 0.5 mg 13/236 (5.5) 20/239 (8.4) 3.14 (13/236/415) 4.51 (20/239/444)
ANCHOR1,2 Sham vs. ranibizumab 0.3 mg 11/143 (7.7) 7/137 (5.1) 4.73 (11/143/233) 2.76 (7/137/254)
Sham vs. ranibizumab 0.5 mg 11/143 (7.7) 11/140 (7.9) 4.73 (11/143/233) 4.42 (11/140/249)
PIER16,17 Sham vs. ranibizumab 0.3 mg 3/62 (4.8) 1/59 (1.7) 3.76 (3/62/80) 0.95 (1/59/105)
Sham vs. ranibizumab 0.5 mg 3/62 (4.8) 2/61 (3.3) 3.76 (3/62/80) 0.95 (1/59/105)
EVEREST19 Sham vs. ranibizumab 0.5 mg 0/21 (0.0) 0/40 (0.0) 0.00 (0/21/11) 0.00 (0/40/20)
Overall Sham vs. ranibizumab 0.3 mg 27/441 (6.1) 25/434 (5.8) 3.71 (27/441/727) 3.12 (25/434/801)
Sham vs. ranibizumab 0.5 mg 27/462 (5.8) 33/480 (6.9) 3.66 (27/462/737) 4.04 (33/480/817)
MI MARINA4 Sham vs. ranibizumab 0.3 mg 5/236 (2.1) 12/238 (5.0) 1.19 (5/236/420) 2.70 (12/238/444)
Sham vs. ranibizumab 0.5 mg 5/236 (2.1) 6/239 (2.5) 1.19 (5/236/420) 1.33 (6/239/452)
ANCHOR1,2 Sham vs. ranibizumab 0.3 mg 3/143 (2.1) 1/137 (0.7) 1.24 (3/143/241) 0.39 (1/137/257)
Sham vs. ranibizumab 0.5 mg 3/143 (2.1) 6/140 (4.3) 1.24 (3/143/241) 2.36 (6/140/254)
PIER16,17 Sham vs. ranibizumab 0.3 mg 1/62 (1.6) 1/59 (1.7) 1.22 (1/62/82) 0.95 (1/59/105)
Sham vs. ranibizumab 0.5 mg 1/62 (1.6) 0/61 (0.0) 1.22 (1/62/82) 0.00 (0/61/107)
EVEREST19 Sham vs. ranibizumab 0.5 mg 0/21 (0.0) 0/40 (0.0) 0.00 (0/21/11) 0.00 (0/40/20)
Overall Sham vs. ranibizumab 0.3 mg 9/441 (2.0) 14/434 (3.2) 1.21 (9/441/743) 1.74 (14/434/806)
Sham vs. ranibizumab 0.5 mg 9/462 (1.9) 12/480 (2.5) 1.19 (9/462/754) 1.44 (12/480/833)
Stroke MARINA4 Sham vs. ranibizumab 0.3 mg 3/236 (1.3) 3/238 (1.3) 0.71 (3/236/423) 0.66 (3/238/452)
Sham vs. ranibizumab 0.5 mg 3/236 (1.3) 9/239 (3.8) 0.71 (3/236/423) 1.99 (9/239/453)
ANCHOR1,2 Sham vs. ranibizumab 0.3 mg 3/143 (2.1) 3/137 (2.2) 1.25 (3/143/240) 1.17 (3/137/256)
Sham vs. ranibizumab 0.5 mg 3/143 (2.1) 0/140 (0.0) 1.25 (3/143/240) 0.00 (0/140/260)
PIER16,17 Sham vs. ranibizumab 0.3 mg 0/62 (0.0) 1/59 (1.7) 0.00 (0/62/83) 0.95 (1/59/105)
Sham vs. ranibizumab 0.5 mg 0/62 (0.0) 0/61 (0.0) 0.00 (0/62/83) 0.00 (0/61/107)
EVEREST19 Sham vs. ranibizumab 0.5 mg 0/21 (0.0) 0/40 (0.0) 0.00 (0/21/11) 0.00 (0/40/20)
Overall Sham vs. ranibizumab 0.3 mg 6/441 (1.4) 7/434 (1.6) 0.81 (6/441/745) 0.86 (7/434/813)
Sham vs. ranibizumab 0.5 mg 6/462 (1.3) 9/480 (1.9) 0.79 (6/462/756) 1.07 (9/480/840)
Stroke þ TIA MARINA4 Sham vs. ranibizumab 0.3 mg 5/236 (2.1) 5/238 (2.1) 1.19 (5/236/421) 1.11 (5/238/451)
Sham vs. ranibizumab 0.5 mg 5/236 (2.1) 12/239 (5.0) 1.19 (5/236/421) 2.67 (12/239/450)
ANCHOR1,2 Sham vs. ranibizumab 0.3 mg 6/143 (4.2) 3/137 (2.2) 2.53 (6/143/237) 1.17 (3/137/256)
Sham vs. ranibizumab 0.5 mg 6/143 (4.2) 4/140 (2.9) 2.53 (6/143/237) 1.56 (4/140/257)
PIER16,17 Sham vs. ranibizumab 0.3 mg 1/62 (1.6) 1/59 (1.7) 1.22 (1/62/82) 0.95 (1/59/105)
Sham vs. ranibizumab 0.5 mg 1/62 (1.6) 1/61 (1.6) 1.22 (1/62/82) 0.94 (1/61/106)
EVEREST19 Sham vs. ranibizumab 0.5 mg 0/21 (0.0) 0/40 (0.0) 0.00 (0/21/11) 0.00 (0/40/20)
Overall Sham vs. ranibizumab 0.3 mg 12/441 (2.7) 9/434 (2.1) 1.62 (12/441/740) 1.11 (9/434/812)
Sham vs. ranibizumab 0.5 mg 12/462 (2.6) 17/480 (3.5) 1.60 (12/462/751) 2.04 (17/480/833)
Vascular Death MARINA4 Sham vs. ranibizumab 0.3 mg 3/236 (1.3) 2/238 (0.8) 0.71 (3/236/424) 0.44 (2/238/453)
Sham vs. ranibizumab 0.5 mg 3/236 (1.3) 3/239 (1.3) 0.71 (3/236/424) 0.66 (3/239/457)
ANCHOR1,2 Sham vs. ranibizumab 0.3 mg 3/143 (2.1) 1/137 (0.7) 1.23 (3/143/243) 0.39 (1/137/258)
Sham vs. ranibizumab 0.5 mg 3/143 (2.1) 1/140 (0.7) 1.23 (3/143/243) 0.38 (1/140/260)
PIER16,17 Sham vs. ranibizumab 0.3 mg 0/62 (0.0) 1/59 (1.7) 0.00 (0/62/83) 0.95 (1/59/105)
Sham vs. ranibizumab 0.5 mg 0/62 (0.0) 0/61 (0.0) 0.00 (0/62/83) 0.00 (0/61/107)
EVEREST19 Sham vs. ranibizumab 0.5 mg 0/21 (0.0) 0/40 (0.0) 0.00 (0/21/11) 0.00 (0/40/20)
Overall Sham vs. ranibizumab 0.3 mg 6/441 (1.4) 4/434 (0.9) 0.80 (6/441/750) 0.49 (4/434/816)
Sham vs. ranibizumab 0.5 mg 6/462 (1.3) 4/480 (0.8) 0.79 (6/462/761) 0.47 (4/480/844)
APTC MARINA4 Sham vs. ranibizumab 0.3 mg 10/236 (4.2) 16/238 (6.7) 2.39 (10/236/419) 3.61 (16/238/443)
Sham vs. ranibizumab 0.5 mg 10/236 (4.2) 14/239 (5.9) 2.39 (10/236/419) 3.12 (14/239/449)
ANCHOR1,2 Sham vs. ranibizumab 0.3 mg 8/143 (5.6) 5/137 (3.6) 3.37 (8/143/237) 1.96 (5/137/255)
Sham vs. ranibizumab 0.5 mg 8/143 (5.6) 7/140 (5.0) 3.37 (8/143/237) 2.75 (7/140/254)
PIER16,17 Sham vs. ranibizumab 0.3 mg 1/62 (1.6) 2/59 (3.4) 1.22 (1/62/82) 1.90 (2/59/105)
Sham vs. ranibizumab 0.5 mg 1/62 (1.6) 0/61 (0.0) 1.22 (1/62/82) 0.00 (0/61/107)
EVEREST19 Sham vs. ranibizumab 0.5 mg 0/21 (0.0) 0/40 (0.0) 0.00 (0/21/11) 0.00 (0/40/20)
Overall Sham vs. ranibizumab 0.3 mg 19/441 (4.3) 23/434 (5.3) 2.57 (19/441/738) 2.87 (23/434/803)
Sham vs. ranibizumab 0.5 mg 19/462 (4.1) 21/480 (4.4) 2.54 (19/462/749) 2.53 (21/480/830)
APTC ¼ Anti-Platelet Trialists Collaboration; ATE ¼ arterial thromboembolic event; MI ¼ myocardial infarction; TIA ¼ transient ischemic attack.
Ophthalmology Retina Volume 2, Number 11, November 2018comparison of ranibizumab 0.5 mg versus sham and ranibizumab
0.3 mg versus sham (Fig 1). Forest plots showing study-level re-
sults and pooled results (using the described modeling approaches)
are summarized in Figure 2 for the 6 key endpoints. For1092comparisons of ranibizumab 0.5 mg or ranibizumab 0.3 mg with
sham, 95% CIs all included 1, indicating no clinically
meaningful treatment differences. KaplaneMeier plots for these
data over time are shown in Figure S3 (available at
Figure 4. Pairwise comparisons of other systemic events in ranibizumab 0.5 mg, ranibizumab 0.3 mg, and sham.a Horizontal bars are 95% conﬁdence
intervals (CIs) of the hazard ratio (HR), reported as Trt 2 vs Trt 1. aCox regression, stratiﬁed by study. bInteraction test for homogeneity from global Cox
regression model adjusting for baseline risk factors. Numbers in the table are rates per 100 patient-years (Rate) and the number of subjects with the event (n)/
number of subjects (N)/number of patient-years (PY). CHF ¼ congestive heart failure; GI ¼ gastrointestinal; Trt ¼ treatment; VTE ¼ venous
thromboembolism.
Zarbin et al  Pooled Safety Analysis of Ranibizumab in nAMDwww.ophthalmologyretina.org). Event proportions and incidence
rates for these systemic endpoints per 100 patient-years are
shown for primary comparisons in Table 3.
When comparing ranibizumab 0.5 mg and 0.3 mg doses, the
rates of MI, stroke (excluding TIA), vascular death, and APTC
events were similar between dose groups (Fig 1). Adjusted HR CIs
for the comparisons between ranibizumab 0.5 mg versus
ranibizumab 0.3 mg did exclude 1 for the stroke or TIA
endpoint (HR, 1.85; 95% CI, 1.13e3.05) and overall ATEs (HR,
1.41; 95% CI, 1.02e1.95). Results from the global and pairwise
models were similar for all endpoints evaluated.
Other Systemic Events
Other systemic endpoints including all-cause death, hypertension,
proteinuria, congestive heart failure, cardiac arrhythmia, acute
renal failure, gastrointestinal hemorrhage or perforation, venous
thromboembolism, and wound healing were similar between
ranibizumab 0.5 mg or 0.3 mg and sham treatment and between
ranibizumab 0.5 mg and 0.3 mg (Fig 4).
Discussion
This pooled analysis evaluates patient-level data from 7
pooled Genentech and Novartis phase II, III, and IV studiescomprising 4080 patients with nAMD, including 1764 and
1854 patients treated with ranibizumab 0.3 and 0.5 mg,
respectively.
Rates of ATE events including MI, stroke (excluding
TIA), stroke or TIA, vascular death, and APTC events were
low over the 1- to 2-year evaluation periods, and there were
no clinically or statistically meaningful treatment differences
observed between ranibizumab 0.5 mg or 0.3 mg versus
sham. None of the measures of MI, stroke, stroke or TIA,
vascular death, or the composites APTC or ATE showed a
signiﬁcant or clinically meaningful difference in this pooled
analysis when comparing ranibizumab 0.5 mg or 0.3 mg
versus sham. These data do not suggest an increased risk of
vascular AEs with ranibizumab 0.5 mg or 0.3 mg compared
with sham in patients with nAMD.
These ﬁndings are consistent with previous meta-
analyses of interventional clinical trials in patients with
nAMD, which generally have not demonstrated an
increased risk of CVAs, major cardiovascular events,
ATEs, or mortality of ranibizumab compared with sham
treatment.26-28 In practice, claims data from the 7 health
administrative databases of Ontario showed no signiﬁcant
increase in risk of stroke, acute MI, venous thromboem-
bolism, or congestive heart failure in patients treated with
ranibizumab.29 Real-world data from the Centers for1093
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with AMD treated with ranibizumab had a signiﬁcantly
lower risk of MI or mortality than patients treated with
verteporﬁn.10,11,30
The randomized clinical trials used in this analysis were
designed to demonstrate the efﬁcacy of the therapeutic
agents involved. Statistically, to demonstrate visual or
anatomic improvement over sham, the trials were sufﬁ-
ciently powered because of robust differences in efﬁcacy.
After the demonstration of efﬁcacy of ranibizumab based on
the sham-controlled randomized clinical trials, it is no
longer ethical to conduct further sham-controlled trials,
limiting the number of patients available for comparisons of
ranibizumab versus sham in a pooled analysis. Another
limitation is created by low event rates (e.g., for stroke
without TIA, for which an upper limit of 3.77 for the HR
was obtained). The incidence rates per 100 patient-years
were 0.8 (sham) and 1.1 (ranibizumab 0.5 mg). Approxi-
mately 1000 patients per group would be required to obtain
an upper conﬁdence limit below 3. With no new sham-
controlled trials being conducted, it will not be possible to
obtain such large numbers of randomized sham-controlled
trials for analysis.
Strengths of the Pooled Analysis
Pooling patient-level data from these 7 combined studies
provides increased precision in estimating treatment
differences and allows for an adjustment for baseline char-
acteristics and for pooling results across studies of differing
durations.31 Availability of the timing of each AE allowed
for KaplaneMeier plots (Fig S3, available at
www.ophthalmologyretina.org) and ﬁtting of Cox
Regression models. The KaplaneMeier plots show event
rates over time incorporating the differing study durations.
The “global model” adjusted for relevant baseline risk fac-
tors. All ﬁtted models were stratiﬁed by study (adjusting for
study differences), and global model results were consis-
tently similar to those of the pairwise comparisons, indi-
cating that adjustment for potential baseline risk factors had
little inﬂuence on the outcome.
This pooled analysis followed a prospective, prespeciﬁed
plan for the pooling of heterogeneous studies, deﬁnition of
endpoints, and analysis methods. To our knowledge, this is
the largest collaborative database of ranibizumab clinical
safety events in patients with nAMD, including Genentech
and Novartis phase II, III, and IV clinical trials.
Limitations of the Pooled Analysis
An inherent limitation of pooled analyses is the pooling of
heterogeneous studies, which differ in study design, inclu-
sion and exclusion criteria, treatment duration, dosing
regimen, PRN re-treatment criteria, patient population, and
region). This analysis combined trials with monthly
treatment (MARINA, ANCHOR, EXTEND I), PRN treat-
ment (EVEREST, SAILOR), and quarterly treatment (PIER,
EXCITE). The primary comparison of ranibizumab 0.5 mg
with sham included mostly monthly-treated patients (82% of
primary comparison population). These analyses were
limited in the extent to which they could evaluate exposure1094to ranibizumab or different dosing regimens. Because the
number of events was low in each group, it was not practical
or meaningful to stratify by treatment regimen.
This analysis did not adjust for multiplicity, which could
increase the probability of chance ﬁndings. For the primary
comparisons, the 95% CIs did intersect 1, so an adjustment
for multiplicity would only widen the CIs.
Many of the events examined in this analysis resulted in
discontinuation of the patient from the study. As such, data
are not typically collected for a patient after treatment
discontinuation. Therefore, for the most part, data on
multiple occurrences of the safety events presented here are
not available.
Meta-analyses, even with increased numbers of patients,
also may be underpowered to evaluate treatment differences
in uncommon safety events.27 A prospectively designed
study with patient numbers similar to this pooled analysis
would be underpowered to detect differences for AEs that
occur infrequently for comparisons with sham (e.g., to
detect 1% vs. 2%, 16% power; 1% vs. 3%, 52% power;
4% vs. 8%, 70% power; 4% vs. 12%, 99% power). Thus,
for stroke, assuming a 1% rate in the sham group, there is
only 52% power to detect a tripling of the risk, whereas
for APTC events assuming a 4% rate in the sham group,
there is 70% power to detect a doubling of the rate.
Composite endpoints may increase power to detect
treatment differences but can mask or dilute the inﬂuence
that any particular component may have shown in isolation.
In the included clinical trials, risk factors for systemic
vascular events were not collected in a standardized way as
for cardiovascular safety studies (e.g., central event adjudi-
cation incorporated for the ascertainment and veriﬁcation of
clinical safety events). The strict inclusion and exclusion
criteria and required visits of clinical trials usually result in
patients who are healthier and more closely followed than
those who receive medical care in clinical practice, and
these patients often receive better care during the clinical
trials. This may limit extrapolation of pooled analysis results
to the wider study population. In ANCHOR, MARINA, and
PIER, there were no exclusion criteria related to cardio-
vascular, cerebrovascular, or peripheral vascular conditions.
SAILOR excluded patients with uncontrolled cardiovascular
disease, and EVEREST, EXTEND I, and EXCITE excluded
patients with prior CVA; however, these studies provided a
small part of the study population for the pertinent
comparisons (EVEREST: 6% for the sham vs. 0.5 mg
comparison; EXTEND I, EXCITE: 8% for the 0.3 mg vs.
0.5 mg comparison).Conclusions
This patient-level, data-pooled analysis draws together the
body of company-sponsored trials, allowing for an increased
sensitivity in detecting infrequent AEs. Within its limita-
tions, this analysis conﬁrmed the low rates of cardiovascular
and cerebrovascular events in patients with nAMD treated
with intravitreal ranibizumab 0.5 mg or 0.3 mg, and these
low rates did not appear to be clinically or statistically
signiﬁcantly different from sham treatment. This analysis
Zarbin et al  Pooled Safety Analysis of Ranibizumab in nAMDadds to the substantial postmarketing experience, and the
results are consistent with the established safety of ranibi-
zumab in patients with nAMD. Taken together, the results
from this pooled analysis support the established
beneﬁterisk proﬁle of ranibizumab in patients with nAMD.
The extrapolation of the ﬁndings of this analysis to the
real-world population is limited by the enrollment criteria of
the selected studies, because the patients in clinical studies
may be healthier and treated more attentively than their
counterparts in the wider population. Although it would not
be ethical to have sham-controlled nAMD studies in the
future because of the signiﬁcant beneﬁt of anti-VEGF
therapy, ongoing safety analyses of real-world data such
as healthcare claims analyses, hospital record analyses, and
observational studies such as LUMINOUS32 should be
continued to further investigate the systemic safety of
ranibizumab in clinical practice.
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